1 completed, 1 withdrawn. 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow Sublocade®: new trials by email Literature Review of Sublocade® trials Research Report on Sublocade®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations Buprenorphine Extended-Release Injection - Opioid Use Disorder | Phase 4 | Completed | Indivior Inc. | 132 | 2023-03-01 | 2025-01-07 |
| Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films Suboxone® SL, Sublocade® - Opioid Use | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2022-06-01 | 2022-06-06 |
Opioid-Related Disorders (1) · Substance-Related Disorders (1)
Indivior Inc. (1) · Wake Forest University Health Sciences (1)
United States (1)
Erin Barnes, MD (1)